Skip to main content

Table 3 Compliance of practice patterns with FSC marketing conditions for prescription according to prior ICS intake, irrespective of FEV 1 availability

From: Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study

  Patients with prior ICS ICS-naïve patients
  GPs (n = 159) Pulmonologists (n = 120) GPs (n = 193) Pulmonologists (n = 238)
Approved prescription condition respected, N (%)     
  FEV1 < 60% predicted1 53 (33.3%) 76 (63.3%) 28 (14.5%) 144 (60.5%)
  History of repeated exacerbations 109 (68.6%) 51 (42.5%) 113 (58.5%) 55 (23.1%)
  Continuous bronchodilator therapy 101 (63.5%) 97 (80.8%) 57 (29.5%) 89 (37.4%)
  All conditions respected (regulatory approval criteria) 25 (15.7%) 31 (25.8%) 6 (3.1%) 16 (6.7%)
Details of conditions respected, N (%)     
  None 15 (9.4%) 6 (5.0%) 53 (27.5%) 47 (19.7%)
  FEV1 only 5 (3.1%) 5 (4.2%) 9 (4.7%) 69 (29.0%)
  Repeated exacerbations only 27 (17.0%) 2 (1.7%) 66 (34.2%) 13 (5.5%)
  Continuous bronchodilator only 18 (11.3%) 28 (23.3%) 13 (6.7%) 28 (11.8%)
  FEV1 and repeated exacerbations only 11 (6.9%) 10 (8.3%) 8 (4.1%) 20 (8.4%)
  FEV1 and bronchodilators only 12 (7.5%) 30 (25.0%) 5 (2.6%) 39 (16.4%)
  Repeated exacerbations and bronchodilators only 46 (28.9%) 8 (6.7%) 33 (17.1%) 6 (2.5%)
  FEV1 and repeated exacerbations +/− bronchodilators 36 (22.6%) 41 (34.2%) 14 (7.3%) 36 (15.1%)
  FEV1 or repeated exacerbations 126 (79.2%) 86 (71.7%) 127 (65.8%) 163 (68.5%)
N conditions respected, N (%)     
  At least one 144 (90.6%) 114 (95.0%) 140 (72.5%) 191 (80.3%)
  At least two 94 (59.1%) 79 (65.8%) 52 (26.9%) 81 (34.0%)
  1. 1Missing FEV1 data were considered non-respect of condition.